248 related articles for article (PubMed ID: 22492714)
1. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
[TBL] [Abstract][Full Text] [Related]
2. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
3. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
[TBL] [Abstract][Full Text] [Related]
4. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
[TBL] [Abstract][Full Text] [Related]
5. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
6. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
7. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
8. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
10. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
[TBL] [Abstract][Full Text] [Related]
11. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
George RE; Li S; Medeiros-Nancarrow C; Neuberg D; Marcus K; Shamberger RC; Pulsipher M; Grupp SA; Diller L
J Clin Oncol; 2006 Jun; 24(18):2891-6. PubMed ID: 16782928
[TBL] [Abstract][Full Text] [Related]
12. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
Fagioli F; Biasin E; Mastrodicasa L; Sandri A; Ferrero I; Berger M; Vassallo E; Madon E
Cancer; 2004 May; 100(10):2215-21. PubMed ID: 15139067
[TBL] [Abstract][Full Text] [Related]
13. Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation.
Hölttä P; Alaluusua S; Saarinen-Pihkala UM; Wolf J; Nyström M; Hovi L
Bone Marrow Transplant; 2002 Jan; 29(2):121-7. PubMed ID: 11850706
[TBL] [Abstract][Full Text] [Related]
14. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation.
Burdach S; Meyer-Bahlburg A; Laws HJ; Haase R; van Kaik B; Metzner B; Wawer A; Finke R; Göbel U; Haerting J; Pape H; Gadner H; Dunst J; Juergens H
J Clin Oncol; 2003 Aug; 21(16):3072-8. PubMed ID: 12915596
[TBL] [Abstract][Full Text] [Related]
18. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
20. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
